Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...
Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment ... we’ve been losing the battle to depression with rates of depression nearly doubling ...
This decision expands the indication of esketamine, offering new hope for patients with treatment-resistant depression(1 Trusted Source FDA approves new nasal spray medication for treatment ...
“Over the past 20 years, we’ve been losing the battle to depression with rates of depression nearly doubling in the [United States],” Gregory Mattingly, MD, principal investigator in ...
An estimated 21 million American adults suffer from clinical depression. © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
randomized placebo-controlled trial that demonstrated “rapid and superior” improvement in Montgomery-Asberg Depression Rating Scale (MADRS) scores with esketamine nasal spray monotherapy ...
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment ...
Hosted on MSN29d
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug ...
"Spravato helps people who suffer from chronic depression feel better. In conjunction with another antidepressant, it has shown a high success rate. Parkside offers this service to reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results